SCHEMBL24029354

SCHEMBL24029354

CC(C)(C)OC(=O)c1ccc(-n2c(S)nc3sccc3c2=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 5/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ CYP2C19 P33261 3/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ LMNA P02545 1/20 0.38
▸ BLM P54132 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ MAPT P10636 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ ABCG2 Q9UNQ0 1/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24029355 0.82 POLB (0.50) POLBMEN1KMT2AALDH1A1LMNA
SCHEMBL109451 0.65 CA1 (0.61) CYP2C19CYP2D6CYP1A2ALDH1A1MAPK1
SCHEMBL2580219 0.65 ALDH1A1 (0.48) KMT2AALDH1A1LMNAMAPK1MAPT
SCHEMBL2675561 0.64 CA12 (0.53) CYP2C19CYP2D6CYP1A2ALDH1A1MAPK1
SCHEMBL4532351 0.64 ELANE (0.60) ALDH1A1LMNAMAPTTSHRABCG2
SCHEMBL29032101 0.63 HSP90AA1 (0.62) ALDH1A1MAPK1CA12CA1CA2
SCHEMBL1704550 0.62 CYP2D6 (0.73) POLBMEN1KMT2ACYP2C19CYP2D6
SCHEMBL38810 0.62 CA12 (0.59) MEN1KMT2ACYP2C19CYP2D6CYP1A2
SCHEMBL1900302 0.62 MPI (0.70) ALDH1A1SMN1; SMN2MAPTNPC1RAB9A
Hydrazine SCHEMBL10771056 0.62 CA12 (0.62) CYP1A2ALDH1A1LMNAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 — — US disclosed
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 — — US disclosed
WO-2021229035-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUNDACIÓN PROFESOR NOVOA SANTOS (ES) 2021-11-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER XIAP, UBQLN1, MDM2 POLB 1121/4885MEN1 3372/4885KMT2A 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback